Trial Profile
Evaluation of Ruxolitinib and Lenalidomide Combination as a Therapy for Patients With Myelofibrosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Ruxolitinib (Primary) ; Prednisone
- Indications Myelofibrosis
- Focus Therapeutic Use
- 18 Oct 2018 Status changed from active, no longer recruiting to completed.
- 28 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 03 Dec 2015 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as per ClinicalTrials.gov record.